Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...

On Tuesday, Embecta Corp (NASDAQ:EMBC) posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents ...

Embecta (EMBC) stock gains as BTIG upgrades the stock citing an end to its patch pump program announced with its Q4 FY24 ...

BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded ...

BofA raised the firm’s price target on Embecta (EMBC) to $20 from $17 and keeps an Underperform rating on the shares after the company ...

Algert Global LLC trimmed its holdings in shares of Embecta Corp. (NASDAQ:EMBC – Free Report) by 31.8% in the third quarter, ...

Q4 2024 Earnings Call Transcript November 26, 2024 Embecta Corp. misses on earnings expectations. Reported EPS is $ EPS, ...

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...

(RTTNews) - Diabetes management company Embecta Corp. (EMBC), which was spun-off from medical technology company Becton, Dickinson and Co. (BDX), announced Tuesday that net income for the fourth ...